Skip to main content
SpringerLink
Log in

Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C=7) and adults with childhood-onset (CO=10) and acquired (A=18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C=0.6 IU/kg/week, CO=0.5 IU/kg/week, A=0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age-and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p<0.001) in C with GHD (mean±SE: 2.9±0.4 ng/ml) than in controls (6.1±0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7±0.5 ng/ml and 3.4±0.2 ng/ml) and controls (3.2±0.2 ng/ml). GH treatment caused a significant increase (p<0.0001) of PIIINP levels both in C (3rd month: 4.4±0.2 ng/ml, 6th month: 5.1±0.4 ng/ml, 12th month: 5.1±0.5 ng/ml), CO-GHD (3rd month: 12.7±1.2 ng/ml; 6th month: 10.2±0.6 ng/ml) and A-GHD (3rd month: 10.0±1.0 ng/ml; 6th month: 8.4±0.6 ng/ml; 12th month: 7.0±0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6±0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6±0.2 ng/ml) were significantly lower (p<0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the “tailored” substitutive dose for the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Risteli L., Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M. (Ed.), Connective tissue in health and disease. CRC Press Inc., Boca Raton, USA, 1990, p. 61.

    Google Scholar 

  2. Fessler J.H., Fessler L.I. Biosynthesis of collagen. Annu. Rev. Biochem. 47: 129, 1978.

    Article  CAS  PubMed  Google Scholar 

  3. Daughaday W.H. Growth hormone and the somatomedins. In: Daughaday W.H. (Ed.), Endocrine control of growth. Elsevier, New York, 1981, p. 1.

    Google Scholar 

  4. Fleischmajer R., Timpl R., Tuderman L., Raisher L., Wiestner M., Perlish J.S., Graves P.N. Ultrastructural identification of extension amino-propeptides of type I and III collagens in human skin. Proc. Natl. Acad. Sci. USA 78: 7360, 1981.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Isaksson O.G.P., Eden S., Jansson J.O. Mode of action of pituitary growth hormone on target cells. Annu. Rev. Physiol. 47: 483, 1985.

    Article  CAS  PubMed  Google Scholar 

  6. Prockop D.J., Kivirikko K.I., Tuderman L., Guzman N.A. The biosynthesis of collagen and its disorders. N. Engl. J. Med. 301: 13, 1979.

    Article  CAS  PubMed  Google Scholar 

  7. Risteli J., Niemi S., Trivedi P., Maentausta O., Mowat A.P., Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin. Chem. 34: 715, 1988.

    CAS  PubMed  Google Scholar 

  8. Salmela P.I., Juustila H., Pyhtinen J., Jokinen K., Alavaikko M., Ruokonen A. Effective clinical response to long term octreotide treatment, with reduced serum of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly. J. Clin. Endocrinol. Metab. 70: 1193, 1990.

    Article  CAS  PubMed  Google Scholar 

  9. Sartorio A., Monzani M., Conti A., Casati G., Faglia G. Serum amino-terminal propeptide of type III procol lagen (PIIINP) levels in patients with acromegaly be fore and after pituitary adenomectomy. Eur. J. Intern. Med. 4: 79, 1993.

    Google Scholar 

  10. Piovesan A., Terzolo M., Reimondo G., Pia A., Codegone A., Osella G., Boccuzzi A., Paccotti P., Angeli A. Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm. Metab. Res. 26: 234, 1994.

    Article  CAS  PubMed  Google Scholar 

  11. Conti A., Sartorio A., Ferrero S., Ferrario S., Ambrosi B. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. J. Endocrinol. Invest. 19: 127, 1996.

    CAS  PubMed  Google Scholar 

  12. Sartorio A., Conti A., Giambona S., Ferrero S., Re T., Passini E., Ambrosi B. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing’s syndrome and in patients with adrenal incidentaloma. Eur. J. Endocrinol. 38: 146, 1998.

    Article  Google Scholar 

  13. Lindstedt G., Weijkum L., Lundberg P.A., Albertsson-Wikland K. Serum procollagen-III as indicator of therapeutic effect in children treated for somatotropin deficiency. Clin. Chem. 15: 1879, 1984.

    Google Scholar 

  14. Tapanainen P., Risteli L., Knip M., Kaar M., Risteli J. Serum aminoterminal propeptide of type III procol lagen: a potential predictor of the response to growth hormone therapy. J. Clin. Endocrinol. Metab. 67: 1244, 1988.

    Article  CAS  PubMed  Google Scholar 

  15. Danne T., Gruters A., Schuppan D., Quantas N., Enders I., Weber B. Relationship of procollagen type III propeptide-related antigens in serum to somatic growth in healthy children and patients with growth disorders. J. Pediatr. 114: 257, 1989.

    Article  CAS  PubMed  Google Scholar 

  16. Trivedi P., Hindmarsh P., Risteli J., Risteli L., Mowat A.P., Brook C.G.D. Growth velocity, growth hormone therapy, and serum concentrations of the aminoterminal propep-tide of type III procollagen. J. Pediatr. 114: 225, 1989.

    Article  CAS  PubMed  Google Scholar 

  17. Sartorio A., Conti A., Morabito F., Monzani M., Faglia G. Serum bone Gla protein and aminoterminal propeptide of type III procollagen levels in patients with GH deficiency before and after met-GH treatment. In: Cavallo L., Job J.C., New M.I. (Eds.), Growth disorders: the state of the art. Raven Press, New York, 1991, p. 329.

    Google Scholar 

  18. Saggese G., Baroncelli G.I., Bertelloni S., Cinquanta L., Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J. Pediatr. 122: 37, 1993.

    Article  CAS  PubMed  Google Scholar 

  19. Vihervuori E., Turpeinen M., Siimes M.A., Koistinen H., Sorva R. Collagen formation and degradation increase during growth hormone therapy in children. Bone 20: 133, 1997.

    Article  CAS  PubMed  Google Scholar 

  20. Trivedi P., Risteli J., Risteli L., Hindmarsh P.C., Brook C.G.D., Mowat A.P. Serum concentrations of type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and in children with growth disorders. Pediatr. Res. 30: 276, 1991.

    Article  CAS  PubMed  Google Scholar 

  21. Amato G., Carella C., Fazio S., La Montagna G., Cittadini A., Sabatini D., Marciano-Mone C., Saccá L., Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 77: 1671, 1993.

    CAS  PubMed  Google Scholar 

  22. Sartorio A., Conti A., Monzani M., Morabito F., Faglia G. Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover. J. Endocrinol. Invest. 16: 893, 1993.

    CAS  PubMed  Google Scholar 

  23. Bengtsson B.A., Edén S., Lonn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tolli J., Sjostrom L., Isaksson O.G.P. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76: 309, 1993.

    CAS  PubMed  Google Scholar 

  24. Sartorio A., Conti A., Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J. 69: 846, 1993.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Bergmann P., Valsamis J., Van Perborgh J., De Schepper J., Van Vliet G. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner’s syndrome treated with recombinant growth hormone. J. Clin. Endocrinol. Metab. 71: 1461, 1990.

    Article  CAS  PubMed  Google Scholar 

  26. Jensen L.T., Jorgensen J.O.L., Risteli J., Christiansen J.S., Lorenzen I. Type I and III procollagen propeptides in growth hormone-deficient patients: effects of increasing doses of GH. Acta Endocrinol. (Copenh.) 124: 278, 1991.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione Malattie Metaboliche III, Istituto Auxologico Italiano, IRCCS, Piancavallo (VB), Via L. Ariosto 13, 20145, Milan, Italy

    A. Sartorio

  2. Laboratorio Sperimentale di Ricerche Endocrinologiche, Istituto Auxologico Italiano, IRCCS, Milano, Italy

    A. Sartorio, A. Conti & S. Ferrero

  3. Istituto di Scienze Endocrine, Ospedale Maggiore, IRCCS, Milano, Italy

    M. Arosio, S. Porretti & G. Faglia

Authors
  1. A. Sartorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Arosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Porretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Faglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sartorio, A., Arosio, M., Conti, A. et al. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency. J Endocrinol Invest 22, 169–175 (1999). https://doi.org/10.1007/BF03343537

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343537

Key-words

Search

Navigation